drugset / Trial / NCT02587962
Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
An ascending dose study in patients with solid tumors to evaluate the safety, tolerability, pharmacodynamics and efficacy of birinapant when given in combination with pembrolizumab. A dose expansion phase of 4 cohorts will also be included.
Timeline
- Start
- 2017-08-04
- Primary completion
- 2020-02-17
- Completion
- 2020-02-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Birinapant | Small molecule | 5.6 mg/m2 | Intravenous |
| Subject | Birinapant | Small molecule | 11 mg/m2 | Intravenous |
| Subject | Birinapant | Small molecule | 17 mg/m2 | Intravenous |
| Subject | Birinapant | Small molecule | 22 mg/m2 | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |